Videos

  Szilard Voros, MD, discusses what he found the most interesting at the 2013 ADA and singles out the new SGLT2 inhibitor class of drugs as especially exciting. However, he cautions that they are very new and only time will tell regarding any safety aspects. He is intrigued by the concept …

Szilard Voros, MD, talks about one of the most surprising aspects of the DPMP testing. Several hundred patients participated initially with their providers. The baseline panel results were given to their doctors who used the results to work with their patients. After the second test, results indicated that around a …

Dr. Cyrus Desouza, MBBS, tells us a little about himself and talks about his work investigating the relationship between cardiovascular disease and diabetes. He is particularly interested in how diabetes drugs affect the cardiovascular system.

Dr. Cyrus Desouza, MBBS, talks about the cardiovascular side effects of newer classes of drugs. SGLT2 inhibitors are still relatively new so there is not much information but they do show some weight loss effects, seem to lower blood pressure, and may have some CV benefits. However, we don’t know what they …

Dr. Cyrus Desouza, MBBS, addresses the controversy around TZD’s especially Avandia. He notes that the initial research in animal models seemed to preserve beta function, raised adiponectin levels, improved endothelial function,and showed beneficial effects on BP. Hoever, with pioglitazone, a debate began on whether they were protective or not because of a retrospective study. …

Dr. Cyrus Desouza, MBBS, discusses why he prescribes Actos, a thiazolidinedione. But he says there are some issues with this kind of drug, particularly weight gain. He does not prescribe actos to patients with high BMI’s and is also cautious because of bladder cancer concerns. Many patients are aware of these issues …

Dr. Cyrus Desouza, MBBS, talks about why he is waiting a little longer before regularly prescribing sodium glucose cotransporter 2 (SGLT2) inhibitors. As an endocrinologist, he feels that, because he deals with very ill patients, it is incumbent upon him that he must also be more careful using a new drug.

Dr. Cyrus Desouza, MBBS, talks about the newest drug class, the sodium glucose cotransporter 2 (SGLT2) inhibitors. He does not regularly prescribe them at this point but if a patient requests a drug he will always research it. He will then discuss the drug and its side effects with his …

Dr. Cyrus Desouza, MBBS, reveals the dark secret behind why patients still use sulfonylureas. Although very effective inititally, the drug is only effective for a limited amount of time and there is beta cell burnout. Dr. Desouza tries not to start patients on sulfonylureas as a second-line; instead he’d rather start with basal …

Dr. Cyrus Desouza, MBBS, talks about the GLP-1s, of which several are already in the market with more in the pipeline. He believes that his is really an exciting class of drugs, particularly because of the weight loss effect, which is a big deal for patients. In addition, there may be …